Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mati Ullah Dad, Ullah"'
Autor:
Iman Waheed Khan, Mati Ullah Dad Ullah, Mina Choudhry, Mukarram Jamat Ali, Muhammad Ashar Ali, Sam L. K. Lam, Pir Ahmad Shah, Satinder Pal Kaur, Daryl T. Y. Lau
Publikováno v:
Microorganisms, Vol 9, Iss 12, p 2607 (2021)
Hepatitis B virus (HBV) infection is a global public health issue and is a major cause of cirrhosis and hepatocellular carcinoma (HCC). Hepatitis D virus (HDV) requires the hepatitis B surface antigen (HBsAg) to replicate. The eradication of HBV, the
Externí odkaz:
https://doaj.org/article/62a1ce57ebcd4b69a7b84b1a14cf9f0b
Autor:
Chaitanya, Allamneni, Ravi S, Vora, Adebowale O, Bamidele, Robert E, Schwartz, Davide, Povero, David M, Salerno, Robert S, Brown, Rosa Lu, Yu, Mati Ullah Dad, Ullah, Daryl T Y, Lau, Wei, Zhang, Amani, Lee, Enis, Kostallari, Nidhi, Jalan-Sakrikar, Shalil, Khanal
Publikováno v:
Hepatology. 74:1727-1729
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f94ed22fff2c42fbf07764926c20697
https://doi.org/10.1002/hep.32146
https://doi.org/10.1002/hep.32146
Autor:
Wajeeha Aiman, Mati Ullah Dad Ullah, Mukarram Jamat Jamat Ali, Iman Waheed Khan, Mina Choudhry, Hafsa Chaudry, Aqsa Anwar, Sreekant Avula, Faiz Anwer, Muhammad Ashar Ali
Publikováno v:
Journal of Clinical Oncology. 40:e21530-e21530
e21530 Background: Melanoma is a cancer of melanocytes and has the potential to metastasize to distant organs. Immune checkpoint inhibitors (ICI) enhance the immune response against cancer cells. Programmed cell death protein-1 (PD-1), PD-ligand-1 (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f82ba344321835bac3c0db93555fbd3b
https://doi.org/10.1200/jco.2022.40.16_suppl.e21530
https://doi.org/10.1200/jco.2022.40.16_suppl.e21530
Autor:
Mina Choudhry, Iman Waheed Khan, Mukarram Jamat Jamat Ali, Mati Ullah Dad Ullah, Muhammad Yasir Anwar, Muhammad Ashar Ali, Wajeeha Aiman
Publikováno v:
Journal of Clinical Oncology. 40:6091-6091
6091 Background: RET proto-oncogene encodes receptor tyrosine kinase. Selpercatinib was the first RET-specific tyrosine kinase inhibitor approved by FDA in RET-altered tumors (pralsetinib was approved afterward). This systematic review and meta-analy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1aee7d0064da6b8c09df2588214f2cfa
https://doi.org/10.1200/jco.2022.40.16_suppl.6091
https://doi.org/10.1200/jco.2022.40.16_suppl.6091